Zacks Investment Research cut shares of Kura Oncology, Inc. (NASDAQ:KURA) from a buy rating to a hold rating in a research report sent to investors on Wednesday, October 18th.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other equities research analysts also recently issued reports on the stock. Leerink Swann reaffirmed an outperform rating and set a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the stock a buy rating in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $16.00 price target on shares of Kura Oncology in a research note on Wednesday, June 28th. ValuEngine downgraded shares of Kura Oncology from a hold rating to a sell rating in a research note on Friday, September 1st. Finally, Cowen and Company initiated coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They set an outperform rating on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $16.00.
Shares of Kura Oncology (NASDAQ KURA) traded down 1.07% during midday trading on Wednesday, reaching $13.85. 901,035 shares of the company’s stock were exchanged. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $15.30. The stock’s market cap is $276.83 million. The company’s 50 day moving average is $13.07 and its 200-day moving average is $9.88.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.03. Equities analysts forecast that Kura Oncology will post ($1.53) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Kura Oncology, Inc. (NASDAQ:KURA) Rating Lowered to Hold at Zacks Investment Research” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/kura-oncology-inc-kura-downgraded-to-hold-at-zacks-investment-research.html.
Institutional investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board bought a new stake in shares of Kura Oncology in the 2nd quarter worth about $102,000. Oppenheimer & Co. Inc. increased its position in shares of Kura Oncology by 14.7% in the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after purchasing an additional 1,600 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Kura Oncology in the 2nd quarter worth about $131,000. Nationwide Fund Advisors bought a new stake in shares of Kura Oncology in the 1st quarter worth about $136,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Kura Oncology in the 2nd quarter worth about $142,000. 40.49% of the stock is currently owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Get a free copy of the Zacks research report on Kura Oncology (KURA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.